|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2001-8-30
|
|
pubmed:abstractText |
In the multicenter trial AML-BFM 93 daunorubicin or idarubicin was randomly applied in all patients during induction in combination with cytarabine and etoposide. After induction all patients were stratified to the standard or high risk group. To improve outcome in high risk patients high dose cytarabine and mitoxantrone (HAM) was introduced. The placing of HAM as either the 2nd or 3rd therapy block was randomized to evaluate the efficacy and toxicity accordingly.
|
|
pubmed:language |
ger
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0300-8630
|
|
pubmed:author |
pubmed-author:AML-BFM-Studien-Gruppe,
pubmed-author:BertholdFF,
pubmed-author:BoonWW,
pubmed-author:CreutzigUU,
pubmed-author:FleischhackGG,
pubmed-author:GadnerHH,
pubmed-author:GnekowAA,
pubmed-author:GraubnerUU,
pubmed-author:HenzeGG,
pubmed-author:HermannJJ,
pubmed-author:ImbachPP,
pubmed-author:JürgensHH,
pubmed-author:KörholzDD,
pubmed-author:KabischHH,
pubmed-author:NiemeyerC MCM,
pubmed-author:ReinhardtDD,
pubmed-author:ReiterAA,
pubmed-author:RitterJJ,
pubmed-author:SpaarH JHJ,
pubmed-author:ZimmermannMM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
213
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
175-85
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11528551-Acute Disease,
pubmed-meshheading:11528551-Adolescent,
pubmed-meshheading:11528551-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11528551-Child,
pubmed-meshheading:11528551-Child, Preschool,
pubmed-meshheading:11528551-Clinical Protocols,
pubmed-meshheading:11528551-Cytarabine,
pubmed-meshheading:11528551-Daunorubicin,
pubmed-meshheading:11528551-Disease-Free Survival,
pubmed-meshheading:11528551-Dose-Response Relationship, Drug,
pubmed-meshheading:11528551-Etoposide,
pubmed-meshheading:11528551-Female,
pubmed-meshheading:11528551-Germany,
pubmed-meshheading:11528551-Humans,
pubmed-meshheading:11528551-Idarubicin,
pubmed-meshheading:11528551-Infant,
pubmed-meshheading:11528551-Infant, Newborn,
pubmed-meshheading:11528551-Leukemia, Myeloid,
pubmed-meshheading:11528551-Male,
pubmed-meshheading:11528551-Mitoxantrone,
pubmed-meshheading:11528551-Prognosis,
pubmed-meshheading:11528551-Remission Induction,
pubmed-meshheading:11528551-Risk,
pubmed-meshheading:11528551-Treatment Outcome
|
|
pubmed:articleTitle |
[Improved treatment results in children with AML: Results of study AML-BFM 93].
|
|
pubmed:affiliation |
Universitäts-Kinderkliniken in Deutschland, Münster, Germany. ucreutzig@aol.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
English Abstract,
Randomized Controlled Trial,
Multicenter Study
|
